Table 3.
Proportion of Subjects with ≥2 -fold Increase in IgG Antibody Concentration for Serotypes 1, 6B, 14, 19F, and 23F (Per-Protocol Immunogenicity Population).
| PPV23 (N = 100) | |||
|---|---|---|---|
| Proportion of Subjects with ≥2-Fold Increase |
|||
| Serotype | n | % | 95% CI†; |
| Group 1 (≥50 years; N = 48) | |||
| 1 | 42 | 87.5 | (74.8, 98.3) |
| 6B | 43 | 89.6 | (77.3, 96.5) |
| 14 | 43 | 89.6 | (77.3, 96.5) |
| 19F | 38 | 79.2 | (65.0, 89.5) |
| 23F | 42 | 87.5 | (74.8, 95.3) |
| Group 2 (2 to 49 years; N = 52) | |||
| 1 | 50 | 96.2 | (86.8, 99.5) |
| 6B | 40 | 76.9 | (63.2, 87.5) |
| 14 | 46 | 88.5 | (76.6, 95.6) |
| 19F | 43 | 82.7 | (69.7, 91.8) |
| 23F | 42 | 80.8 | (67.5, 90.4) |
†
Based on the 2-sided exact CI method for a single binomial proportion.
‡
N = Total number of subjects with evaluable serology at Prevaccination and Postvaccination.
§
n = Total number of subjects with IgG ≥2-fold increase.
CI = confidence interval